AlphaQuest LLC Lowers Position in Zimmer Biomet Holdings, Inc. $ZBH

AlphaQuest LLC decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 43.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,882 shares of the medical equipment provider’s stock after selling 2,238 shares during the period. AlphaQuest LLC’s holdings in Zimmer Biomet were worth $263,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Columbia River Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the first quarter valued at about $30,000. Accent Capital Management LLC acquired a new stake in Zimmer Biomet in the 1st quarter worth about $35,000. Cullen Frost Bankers Inc. boosted its holdings in Zimmer Biomet by 1,452.4% in the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 305 shares during the last quarter. Hilltop National Bank purchased a new stake in Zimmer Biomet during the 2nd quarter worth approximately $42,000. Finally, Zions Bancorporation National Association UT acquired a new position in shares of Zimmer Biomet during the first quarter valued at approximately $48,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $100.77 on Friday. The company’s 50-day moving average is $101.45 and its two-hundred day moving average is $97.62. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a market capitalization of $19.96 billion, a price-to-earnings ratio of 24.52, a PEG ratio of 2.29 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the previous year, the company earned $2.01 EPS. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of research analyst reports. Raymond James Financial lifted their price target on Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Rothschild & Co Redburn began coverage on Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Finally, Royal Bank Of Canada set a $111.00 price target on shares of Zimmer Biomet in a research note on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $111.94.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.